Acadia Pharmaceuticals Inc. logo

Acadia Pharmaceuticals Inc. (ACAD)

Market Closed
28 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
22. 62
-0.63
-2.71%
$
3.73B Market Cap
- P/E Ratio
0% Div Yield
1,736,216 Volume
-0.34 Eps
$ 23.25
Previous Close
Day Range
22.58 23.26
Year Range
13.4 25.23
Want to track ACAD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 2 days
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 0 year ago
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe

Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe

Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.

Zacks | 1 year ago
Acadia Pharmaceuticals: Back In The Buy Zone

Acadia Pharmaceuticals: Back In The Buy Zone

Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trading at two times FY24 revenue net of cash. An updated analysis around Acadia Pharmaceuticals follows in the paragraphs below.

Seekingalpha | 1 year ago
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?

Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago